- Home
- AEAQ vs LXEO Comparison
AEAQ vs LXEO Comparison
Compare AEAQ & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | AEAQ | LXEO |
|---|---|---|
| Founded | 2025 | 2017 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 315.6M | 348.7M |
| IPO Year | 2025 | 2023 |
Fundamental Metrics
Financial Performance| Metric | AEAQ | LXEO |
|---|---|---|
| Price | $10.12 | $3.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $20.67 |
| AVG Volume (30 Days) | 111.5K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.87 | $2.55 |
| 52 Week High | $10.15 | $10.99 |
Technical Indicators
Market Signals| Indicator | AEAQ | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 60.50 | 48.27 |
| Support Level | $9.88 | $2.98 |
| Resistance Level | N/A | $3.56 |
| Average True Range (ATR) | 0.01 | 0.31 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 57.14 | 54.43 |
Price Performance
Historical ComparisonAbout AEAQ Activate Energy Acquisition Corp. Class A Ordinary Share
Activate Energy Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.